Should I buy or sell Ovid Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OVID shares. View OVID analyst ratings or view top-rated stocks .

What is Ovid Therapeutics' stock price target for 2024?

3 equities research analysts have issued twelve-month price targets for Ovid Therapeutics' stock. Their OVID share price targets range from $8.00 to $11.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 180.4% from the stock's current price. View analysts price targets for OVID or view top-rated stocks among Wall Street analysts .

How have OVID shares performed in 2024?

Ovid Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, OVID stock has decreased by 0.3% and is now trading at $3.21. View the best growth stocks for 2024 here .

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 2,800,000 shares, a drop of 23.7% from the March 15th total of 3,670,000 shares. Based on an average daily volume of 205,000 shares, the days-to-cover ratio is presently 13.7 days. Currently, 4.8% of the company's stock are short sold. View Ovid Therapeutics' Short Interest .

When is Ovid Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our OVID earnings forecast .

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) issued its quarterly earnings results on Friday, March, 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The firm earned $0.14 million during the quarter, compared to the consensus estimate of $0.10 million. Ovid Therapeutics had a negative net margin of 13,351.53% and a negative trailing twelve-month return on equity of 49.76%.

What other stocks do shareholders of Ovid Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , Allena Pharmaceuticals (ALNA) , Corbus Pharmaceuticals (CRBP) , SCYNEXIS (SCYX) , Enphase Energy (ENPH) , Gilead Sciences (GILD) and Novavax (NVAX) .

When did Ovid Therapeutics IPO?

Ovid Therapeutics (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OVID

Ovid Therapeutics (OVID) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free OVID Stock Alerts

$3.21

+0.10 (+3.22%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.12
▼
$3.24
50-Day Range: $2.72
▼
$4.04
52-Week Range: $2.57
▼
$4.14

Volume: 226,837 shs
Average Volume: 197,516 shs
Market Capitalization: $226.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get Ovid Therapeutics alerts:

Ovid Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 180.4% Upside
$9.00 Price Target
Short Interest: Healthy
4.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.96
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$50,364 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.65) to ($0.20) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

77th out of 918 stocks

Pharmaceutical Preparations Industry

22nd out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Ovid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ovid Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.78% of the float of Ovid Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Ovid Therapeutics has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Ovid Therapeutics has recently decreased by 23.71%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ovid Therapeutics does not currently pay a dividend.
Dividend Growth
Ovid Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ovid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Ovid Therapeutics is -0.85.

3.3

News and Social Media Coverage

News Sentiment
Ovid Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Ovid Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
4 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ovid Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,364.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
12.60% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ovid Therapeutics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ovid Therapeutics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ovid Therapeutics has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Ovid Therapeutics Stock (NASDAQ:OVID)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

OVID Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OVID Stock News Headlines

March 21, 2024 | insidertrades.com

Ovid Therapeutics Inc. (NASDAQ:OVID) CEO Jeremy M. Levin Acquires 18,248 Shares

April 18, 2024 | finance.yahoo.com

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | msn.com

Ovid Therapeutics gains on bullish view at Wedbush

April 4, 2024 | globenewswire.com

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024 | msn.com

Marinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy Treatment

March 29, 2024 | bizjournals.com

Marinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twist

March 22, 2024 | investing.com

Ovid therapeutics CEO acquires $50k in company stock

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 22, 2024 | finance.yahoo.com

Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying

March 17, 2024 | insidermonkey.com

5 Oversold Biotech Stocks To Buy Right Now

March 13, 2024 | markets.businessinsider.com

Ovid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic Partnerships

March 13, 2024 | news.yahoo.com

Ovid gas station, state and local officials dealing with contaminated fuel problem

March 13, 2024 | msn.com

Ovid gas station shut down after discovery of water inside pumps

March 11, 2024 | markets.businessinsider.com

TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

March 9, 2024 | finance.yahoo.com

OVID Oct 2024 7.500 call

March 8, 2024 | benzinga.com

Recap: Ovid Therapeutics Q4 Earnings

March 8, 2024 | globenewswire.com

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | investing.com

Ovid Therapeutics Inc (OVID)

February 28, 2024 | globenewswire.com

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

February 22, 2024 | news.yahoo.com

Ovid-Elsie girls win third straight conference title

February 17, 2024 | finance.yahoo.com

OVID Mar 2024 5.000 call

February 17, 2024 | finance.yahoo.com

OVID Apr 2024 5.000 call

February 15, 2024 | msn.com

Taysha transfers rights to 3 programs, extends cash runway into 2026

February 6, 2024 | finance.yahoo.com

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 1, 2024 | msn.com

Circulatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illness

January 18, 2024 | finance.yahoo.com

Owning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID),

See More Headlines

Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OVID
CUSIP: N/A
CIK: 1636651
Web: www.ovidrx.com
Phone: (646) 661-7661
Fax: N/A
Employees: 40
Year Founded: 2014

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $11.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +181.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,340,000.00
Net Margins: -13,351.53%
Pretax Margin: -13,351.79%
Return on Equity: -49.76%
Return on Assets: -38.16%

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 9.55
Quick Ratio: 9.55

Sales & Book Value

Annual Sales: $390,000.00
Price / Sales: 580.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.24 per share
Price / Book: 2.58

Miscellaneous

Outstanding Shares: 70,710,000
Free Float: 61,801,000
Market Cap: $226.27 million
Optionable: Optionable
Beta: 0.71

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jeremy Max Levin Ba Zoology (Age 71)
Dphil, Mb Bchir, President, CEO & Chairman
Comp: $923.54k
Mr. Jeffrey A. Rona (Age 56)
Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer
Comp: $686.28k
Mr. Jason Tardio M.B.A. (Age 46)
Chief Operating Officer
Comp: $652.84k
Ms. Lora Pike
Senior Director of Investor Relations & Public Relations
Mr. Thomas Michael Perone J.D. (Age 58)
M.B.A., General Counsel
Comp: $632.11k
Mr. Simon D. Kelner (Age 50)
Chief Human Resources Officer
Dr. Dirk Haasner (Age 59)
Senior Vice President of Global Manufacturing & CMC QA
Comp: $416.95k
Dr. Todd F. Baumgartner M.D.
M.P.H., Senior Vice President of Regulatory Affairs
Dr. Julia Tsai Ph.D. (Age 49)
Senior Vice President of Clinical Development
Ms. Meg Alexander
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OVID Stock Analysis - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OVID shares.
View OVID analyst ratings or view top-rated stocks.
What is Ovid Therapeutics' stock price target for 2024?: 3 equities research analysts have issued twelve-month price targets for Ovid Therapeutics' stock. Their OVID share price targets range from $8.00 to $11.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 180.4% from the stock's current price.
View analysts price targets for OVID or view top-rated stocks among Wall Street analysts.
How have OVID shares performed in 2024?: Ovid Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, OVID stock has decreased by 0.3% and is now trading at $3.21.
View the best growth stocks for 2024 here.
Are investors shorting Ovid Therapeutics?: Ovid Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 2,800,000 shares, a drop of 23.7% from the March 15th total of 3,670,000 shares. Based on an average daily volume of 205,000 shares, the days-to-cover ratio is presently 13.7 days. Currently, 4.8% of the company's stock are short sold.
View Ovid Therapeutics' Short Interest.
When is Ovid Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our OVID earnings forecast.

How were Ovid Therapeutics' earnings last quarter?: Ovid Therapeutics Inc. (NASDAQ:OVID) issued its quarterly earnings results on Friday, March, 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The firm earned $0.14 million during the quarter, compared to the consensus estimate of $0.10 million. Ovid Therapeutics had a negative net margin of 13,351.53% and a negative trailing twelve-month return on equity of 49.76%.
What other stocks do shareholders of Ovid Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).
When did Ovid Therapeutics IPO?: Ovid Therapeutics (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
How do I buy shares of Ovid Therapeutics?: Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OVID) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial